Prozac Study Fails to Show Effective Reduction of Autism Behaviors
Posted Feb 24 2009 12:00am
By Kim Stagliano
Those of us in the autism treatment community seem to know instinctively that you can not simply "drug away" (mask) the behaviors associated with autism. It was disappointing to read Autism Speaks' Peter Bell's statement about "treating the core symptoms" of autism. No. We need to determine what is causing the symptoms. It's time for autism to be treated as a true medical diagnosis and get it OUT of the psychology-psychiatric-behavioral ghetto. We've done that in the treatment community. Come on, Autism Speaks. Join us.
Autism Speaks Announces Results Reported for the Study of Fluoxetine in Autism (SOFIA) First Industry-Sponsored Trial for the Autism Clinical Trials Network (ACTN)
NEW YORK, N.Y. (February 18, 2009) – Autism Speaks today announced initial results reported for the first industry-sponsored trial of the Autism Clinical Trials Network (ACTN), the Study of Fluoxetine in Autism (SOFIA). These results showed that fluoxetine was not effective for reducing repetitive behaviors in children and adolescents with Autistic Disorder as compared to placebo (non-medicinal sugar pill).